Peritoneal
malignant mesothelioma is a rare disorder with a poor prognosis, and a standard treatment for it has not yet been established. Therefore, treatment of this disorder tends to be selected according to pleura
malignant mesothelioma. We analyzed case reports in Japan. The median survival time(MST)with this disease was 12 months and the 1-year survival rate was 47. 3% in the
chemotherapy group. It was found through a case-series study that
platinum pharmaceutical plus
antimetabolite are effective against peritoneal
malignant mesothelioma. A
gemcitabine(GEM)plus
cisplatin(CDDP)regimen had been selected as a conventional treatment, but subsequently,
pemetrexed(
MTA)was covered by health insurance for pleural
malignant mesothelioma in 2007, and the
MTA plus CDDP regimen became the standard treatment. However, a phase III trial of GEM plus CDDP regimen and
MTA plus CDDP regimen was not performed. There is a need to perform these phase III trials in the future. In our institution, the
MTA plus CDDP regimen was the first-line treatment, and the GEM plus CDDP regimen was the second-line treatment against peritoneal
malignant mesothelioma.
Palonosetron hydrochloride and
aprepitant should be used actively in treatment. Also,
carboplatin(
CBDCA)is effective as an alternative
therapy of the CDDP against renal disorder case, but hematotoxicity requires attention.